Catalog No.
Product Name
Application
Product Information
Citations
-
dual 5alpha-reductase inhibitor
Dutasteride is a dual 5-a reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT).- Makoto Ishikawa, .et al. , Sci Rep, 2018, 8: 12851 PMID: 30150786
- Makoto Ishikawa, .et al. , Neuropharmacology, 2016, Dec; 111: 142-159 PMID: 27596950
- Makoto Ishikawa, .et al. , Invest Ophthalmol Vis Sci, 2014, 55(12): 8531-8541 PMID: 25406290
- Finasteride is a synthetic type II 5α-reductase inhibitor. This enzyme converts testosterone to dihydrotestosterone (DHT).
- Chen CC, .et al. , Anticancer Res, 2017, Dec;37(12):6893-6898 PMID: 29187470
-
5-alpha reductase inhibitor
β-sitosterol reduces blood levels of cholesterol, and is sometimes used in treating hypercholesterolemia. β-Sitosterol inhibits cholesterol absorption in the intestine. When the sterol is absorbed in the intestine, it is transported by lipoproteins and incorporated into the cellular membrane. - Chlormadinone acetate is a steroidal progestin with additional antiandrogen and antigonadotropic effects, used often in combinations as an oral contraceptive.
-
5 alpha-reductase inhibitor
Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. -
testosterone 5-alpha-reductase inhibitor
Finasteride (acetate) is an orally active testosterone 5-alpha-reductase inhibitor. -
5α-reductase inhibitor
Finasteride Carboxaldehyde is a metabolite of Finasteride in human bile (M2 metabolite) that can be used for proteomics research. -
5α-Reductase Isozyme Inhibitor
Dihydro Dutasteride is a metabolite of Dutasteride, functioning as a potent inhibitor of both isoforms of the 5α-reductase enzyme. This compound exhibits significant biological activity in the modulation of androgen levels, making it valuable for research applications related to prostate health and hair loss disorders. Its inhibitory effects on 5α-reductase facilitate investigations into androgen metabolism and related pathologies. -
5α-Reductase Isozyme Inhibitor
5β-Dutasteride is a selective inhibitor of both isoforms of 5α-reductase. By inhibiting this enzyme, it effectively reduces the conversion of testosterone to dihydrotestosterone (DHT), making it valuable in studying androgen-related disorders. Its potent biological activity supports research applications in androgen-related conditions, including benign prostatic hyperplasia and androgenetic alopecia. -
testosterone 5α-reductase Inhibitor, 5α-dihydrotestosterone receptor Inhibitor
Kushenol Q is an inhibitor of testosterone 5α-reductase and the 5α-dihydrotestosterone receptor. This compound demonstrates significant biological activity in modulating androgen signaling pathways, making it useful in studies related to hormone-related disorders. Additionally, Kushenol Q exhibits antibacterial properties against Gram-positive bacteria, indicating its potential in antimicrobial research applications. -
5 alpha Reductase Inhibitor
12-O-Methylcarnosic acid is a potent inhibitor of 5 alpha reductase, exhibiting an IC50 value of 61.7 μM. Isolated from the acetone extract of Salvia microphylla, this diterpene demonstrates significant anti-proliferative effects in LNCaP prostate cancer cells. In addition to its role in cancer research, 12-O-Methylcarnosic acid also possesses antioxidant and antimicrobial properties, making it a valuable reagent for various biological studies. -
5α-Reductase Inhibitor
Lapisteride is a potent 5α-reductase inhibitor, demonstrating efficacy in the modulation of androgen metabolism. This compound effectively inhibits 5α-reductase activity within hair follicles, making it a valuable tool for investigating prostatic hyperplasia and androgenic alopecia. Its applications extend to research aimed at understanding androgen-related disorders and developing targeted therapies. -
5-Alpha Reductase Inhibitor
CGP-53153 is a steroidal inhibitor of 5-alpha reductase, exhibiting IC50 values of 36 nM in rat prostatic tissue and 262 nM in human prostatic tissue. This compound is primarily utilized in research to investigate the inhibition of 5-alpha reductase, which plays a crucial role in androgen metabolism. Its biological activity makes it a valuable tool for studying conditions related to androgen levels, such as benign prostatic hyperplasia and prostate cancer. -
5α-Reductase Inhibitor
Izonsteride is a potent inhibitor of 5α-reductase, demonstrating IC50 values of 11.6 nM for type I and 7.37 nM for type II isoforms. By hindering the enzyme responsible for converting testosterone to dihydrotestosterone, Izonsteride effectively reduces androgenic activity. This compound has been shown to significantly inhibit the growth of LNCaP tumors in thymic mice, indicating its potential as a therapeutic agent in prostate cancer research, with minimal host toxicity observed. -
5 alpha Reductase Inhibitor
MK 386 is a selective inhibitor of 5-alpha reductase type I, which plays a critical role in the metabolism of testosterone into dihydrotestosterone (DHT). By inhibiting this enzyme, MK 386 is utilized in research focused on prostate cancer treatment and hormone-related disorders. Its specificity for 5-alpha reductase I makes it a valuable tool for studying the effects of DHT modulation on cellular and molecular pathways associated with prostate cancer progression. -
Steroid 5α-Reductase Inhibitor
8,11-Eicosadiynoic acid is a steroid 5α-reductase inhibitor that exhibits potent biological activity in the modulation of androgen metabolism. This unsaturated fatty acid is primarily utilized in research related to acne and other androgen-mediated conditions. Its ability to inhibit 5α-reductase makes it a valuable tool for investigating pathways involved in sebaceous gland function and acne pathology. -
5α-reductase Inhibitor
Bexlosteride is a benzoquinolinone that acts as a specific inhibitor of human type I 5α-reductase. It exhibits significant metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. This compound is valuable for research focused on prostate cancer, providing insights into the modulation of androgen pathways and potential therapeutic interventions. -
5alpha-reductase 1 Inhibitor
AS-601811 is a potent inhibitor of 5α-reductase 1, demonstrating an IC50 of 20 nM. This compound is valuable for investigating conditions such as alopecia and hirsutism by modulating androgen metabolism. Its specificity for 5α-reductase 1 makes it an essential tool for research into related endocrine and dermatological disorders. -
5 alpha Reductase Inhibitor
ONO-3805 is a non-steroidal 5α-reductase inhibitor that selectively targets the enzyme responsible for converting testosterone to dihydrotestosterone. It exhibits potential therapeutic benefits in the management of benign prostatic hyperplasia and may contribute to the reduction of associated symptoms. This compound is primarily utilized in endocrine-related research and studies focusing on androgen modulation in prostatic disorders. -
Human Type I 5α-Reductase Inhibitor
LY191704 is a selective, nonsteroidal inhibitor of human type I 5α-reductase, exhibiting noncompetitive inhibition. This compound, a racemic mixture of LY300502 and LY300503, demonstrates potent activity in modulating the enzymatic conversion of testosterone to dihydrotestosterone (DHT). LY191704 is valuable for investigating human endocrine disorders linked to elevated DHT levels, offering insights into potential therapeutic approaches for conditions such as androgenetic alopecia and benign prostatic hyperplasia. -
5 alpha Reductase Inhibitor
L-751788 is a selective inhibitor of type I 5α-reductase, a key enzyme involved in steroid metabolism. This compound demonstrates significant potential in reducing dihydrotestosterone levels without adversely affecting fetal external genitalia, as evidenced by studies conducted in pregnant rhesus monkeys. L-751788 is valuable for research applications investigating disorders of androgen metabolism and related therapeutic interventions. -
5α-reductase Activator
Glutamic acid-alanine-glycine mixture serves as an activator of testosterone 5α-reductase, enhancing its enzymatic activity and promoting prostate function through elevated free amino acid levels. This compound demonstrates a complex interaction with testosterone and estradiol, as it inhibits 5α-reductase activity in combination, leading to decreased free amino acids. The mixture is valuable for research into prostate health and endocrine disorders, providing insights into regulatory mechanisms of steroid metabolism. -
5a-reductase Inhibitor
(15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one is a potent inhibitor of 5α-reductase, exhibiting an IC50 value of 41.9 μM. This compound effectively inhibits testosterone-induced growth in the ventral prostate of rat models. It holds potential for research applications focused on benign prostatic hyperplasia (BPH) and other conditions linked to 5α-dihydrotestosterone (DHT), including acne and male pattern baldness. -
5 alpha-Reductase Inhibitor
Turosteride is a selective inhibitor of 5 alpha-reductase, demonstrating IC50 values of 55 nM and 53 nM for human and rat prostatic enzymes, respectively. This compound effectively reduces prostate and seminal vesicle weights, making it valuable in research related to benign prostatic hyperplasia and androgenic activity modulation. Turosteride can be instrumental in studies investigating the role of 5 alpha-reductase in prostatic diseases and hormone regulation. -
Steroid 5α-Reductase Inhibitor
MK-0434 is an orally active inhibitor of steroid 5α-reductase, acting primarily to inhibit the conversion of testosterone into dihydrotestosterone (DHT). By reducing DHT levels, MK-0434 plays a significant role in the investigation of benign prostatic hyperplasia and other androgen-mediated conditions. This compound serves as a useful tool for researchers studying the hormonal pathways involved in prostate health and related disorders. -
5α-reductase Inhibitor
MK-0963 is a steroidal inhibitor of 5α-reductase, effectively reducing serum dihydrotestosterone (DHT) levels in a dose-dependent manner. This compound is valuable for studying dihydrotestosterone-related conditions, including benign prostatic hyperplasia (BPH). Its ability to modulate DHT concentrations makes MK-0963 a significant tool in research aimed at understanding and treating disorders associated with androgen metabolism. -
5α-Reductase Inhibitor
FR-146687 is a selective and orally bioavailable inhibitor of 5α-reductase, demonstrating IC50 values of 1.7 nM and 4.6 nM for rat and human enzymes, respectively. This compound exhibits specific inhibitory activity without affecting other steroid oxidoreductases. FR-146687 is utilized in research focused on disorders related to androgen metabolism and can aid in the development of therapeutic interventions targeting 5α-reductase-related pathways. -
5 alpha Reductase Inhibitor
5α-reductase-IN-1 is a potent inhibitor of 5α-reductase, an enzyme implicated in androgen metabolism. This compound is primarily utilized in research focused on androgenetic alopecia and may be investigated in conjunction with minoxidil to explore synergistic effects in hair regrowth studies. Its role in modulating testosterone derivatives offers valuable insights into potential therapeutic strategies for hair loss disorders.
